Kyverna Therapeutics (KYTX) Expected to Announce Quarterly Earnings on Wednesday

Kyverna Therapeutics (NASDAQ:KYTX) is expected to be issuing its Q3 2025 results before the market opens on Wednesday, November 12th. Analysts expect the company to announce earnings of ($0.94) per share for the quarter. Individuals may visit the the company’s upcoming Q3 2025 earningresults page for the latest details on the call scheduled for Thursday, November 13, 2025 at 4:00 PM ET.

Kyverna Therapeutics (NASDAQ:KYTX) last announced its quarterly earnings results on Tuesday, August 12th. The company reported ($0.97) EPS for the quarter, beating the consensus estimate of ($1.00) by $0.03. On average, analysts expect Kyverna Therapeutics to post $-3 EPS for the current fiscal year and $-4 EPS for the next fiscal year.

Kyverna Therapeutics Trading Down 7.6%

Shares of NASDAQ:KYTX opened at $6.36 on Wednesday. The firm’s 50 day moving average is $5.71 and its two-hundred day moving average is $3.97. Kyverna Therapeutics has a 52 week low of $1.78 and a 52 week high of $8.45. The firm has a market capitalization of $275.07 million, a P/E ratio of -1.73 and a beta of 3.79.

Wall Street Analyst Weigh In

Several equities research analysts have commented on the stock. Weiss Ratings restated a “sell (e+)” rating on shares of Kyverna Therapeutics in a research note on Tuesday, October 14th. William Blair assumed coverage on shares of Kyverna Therapeutics in a research note on Wednesday, August 20th. They issued an “outperform” rating on the stock. Wells Fargo & Company raised their price target on shares of Kyverna Therapeutics from $27.00 to $31.00 and gave the company an “overweight” rating in a research note on Wednesday, October 29th. Finally, HC Wainwright raised their price objective on shares of Kyverna Therapeutics from $10.00 to $20.00 and gave the company a “buy” rating in a research note on Monday, October 27th. Four investment analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company. According to data from MarketBeat, Kyverna Therapeutics has a consensus rating of “Moderate Buy” and an average price target of $23.67.

Institutional Trading of Kyverna Therapeutics

Large investors have recently added to or reduced their stakes in the business. Qube Research & Technologies Ltd bought a new stake in Kyverna Therapeutics during the second quarter worth approximately $43,000. Bank of America Corp DE boosted its holdings in Kyverna Therapeutics by 41.6% during the fourth quarter. Bank of America Corp DE now owns 21,788 shares of the company’s stock worth $81,000 after buying an additional 6,400 shares in the last quarter. Rhumbline Advisers boosted its holdings in Kyverna Therapeutics by 22.0% during the first quarter. Rhumbline Advisers now owns 31,614 shares of the company’s stock worth $61,000 after buying an additional 5,694 shares in the last quarter. XTX Topco Ltd bought a new stake in Kyverna Therapeutics during the second quarter worth approximately $107,000. Finally, Federated Hermes Inc. boosted its holdings in Kyverna Therapeutics by 22.2% during the second quarter. Federated Hermes Inc. now owns 44,000 shares of the company’s stock worth $135,000 after buying an additional 8,000 shares in the last quarter. 18.08% of the stock is currently owned by institutional investors.

Kyverna Therapeutics Company Profile

Kyverna Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on developing cell therapies for patients suffering from autoimmune diseases. Its lead product candidate is KYV-101, an autologous CD19 CAR T-cell product candidate for the treatment of patients with lupus nephritis and systemic sclerosis that is in Phase I clinical trial; and for myasthenia gravis and multiple sclerosis that is in Phase II clinical trial.